Clinical Trial Update: Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 [Phase 1]

View source ↗

Summary

Phase 1 trial update showing safety and tolerability of AP 12009 (Trabedersen) administered intravenously in patients with advanced tumors overproducing TGF-bet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Pancreatic Cancer

Drugs mentioned

• AP 12009 (Trabedersen) (Trabedersen)

Snippet

Sponsor: Isarna Therapeutics GmbH | Conditions: Pancreatic Neoplasms, Melanoma | Phase 1 | Status: COMPLETED